CNR1 and metabolic syndrome: Chronic administration of ZnO nanoparticles by oral route induced dyslipidemia and atherosclerotic lesions, which was accompanied by alterations at the structural level, CB1 and CB2 receptor expression, vascular contractility, and increased blood pressure.